Matsumoto, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 ( Shiba-Kyoritsu )

Position

Professor

Career 【 Display / hide 】

  • 2003.04
    -
    2007.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04
    -
    2014.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04
    -
    2017.03

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04
    -
    Present

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 1994.04
    -
    1998.03

    Kumamoto University, 薬学部, 薬学科

    University, Graduated

  • 1998.04
    -
    2000.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Master's course

  • 2000.04
    -
    2003.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, Kumamoto University, Coursework, 2003.03

    α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Clinical pharmacy

Page Top ▲

Research Keywords 【 Display / hide 】

  • Pharmacokinetics/Pharmacodynamics

  • Therapeutic drug monitoring

  • 抗菌化学療法

  • 高齢者医療

Page Top ▲

Research Themes 【 Display / hide 】

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

    2014.04
    -
    Present

Page Top ▲
 

Books 【 Display / hide 】

  • 今日の治療薬2026

    松元一明, 南江堂, 2026.01

  • 今日の治療指針2026

    松元一明, 医学書院, 2026.01

    Scope: 市中肺炎/疥癬, アタマジラミ症/急性中耳炎　服薬指導・薬剤情報

  • 感染症学

    松元一明, 南山堂, 2025.02,  Page： 222-236

    Scope: 中枢神経系感染症.

  • 今日の治療薬2025

    松元一明, 南江堂, 2025.01

  • 今日の治療指針2025

    松元一明, 医学書院, 2025.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

    Mizukami Y., Takahashi M., Suzuki K., Duan S., Ikegami S., Muraishi T., Satake N., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

    Journal of Infection and Chemotherapy 32 ( 1 ) 102889 2026.01

    Joint Work,  ISSN  1341321X

    　View Summary

    Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients

    Komatsu T., Tomizawa A., Samura M., Suzuki A., Ishigo T., Fujii S., Ibe Y., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Nagumo F., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Otori K., Matsumoto K.

    Journal of Infection and Chemotherapy 31 ( 12 ) 102838 2025.12

    Joint Work,  ISSN  1341321X

    　View Summary

    Introduction: This study aimed to develop and evaluate a population pharmacokinetic model and optimal dosing regimen for vancomycin in overweight and obese adults. Methods: A population pharmacokinetic model using a two-compartment system was constructed using a nonlinear mixed-effects approach, incorporating 527 data points from 184 participants. External validation of the model was carried out using an additional 55 data points from 21 participants; these were not used in the construction of the model. Monte Carlo simulations were used to determine the dosage that achieved the steady state area under the curve value falling between 400 μg h/mL and 600 μg h/mL. Results: In the final model, vancomycin clearance was found to be a significant predictor of blood vancomycin levels, alongside creatinine clearance (CCr), blood urea nitrogen levels, and incidence of heart failure. CCr was calculated with adjusted body weight (AdjBW). AdjBW was selected as a predictor of the volume of distribution in the central and peripheral compartments. External validation showed that the highest proportion of cases had deviations of less than 15 % between measured and predicted values in the final model developed in this study. This indicates that our model outperforms previously developed models (five for obese patients and four for non-obese patients). Conclusions: Our model shows that determining effective vancomycin doses for overweight and obese patients depend on estimated CCr rates, AdjBW, BUN levels, and incidence of heart failure.

  • Evaluating the Necessity of Two-Point Sampling for Vancomycin Area Under the Curve in Follow-up Therapeutic Drug Monitoring.

    Suzuki A, Fujihara H, Yamaguchi F, Yoshida H, Tanaka H, Yagi Y, Maruyama T, Hamada Y, Ishigo T, Fujii S, Nagumo F, Samura M, Chiba H, Ebihara F, Takuma A, Komatsu T, Tomizawa A, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 31 ( 11 ) 102821 2025.09

    Joint Work,  ISSN  1341-321X

    　View Summary

    Objective: While both peak and trough (two-point) sampling are recommended to estimate the area under the concentration-time curve (AUC) for vancomycin, one-point sampling may reduce clinical burden. This study aimed to identify patient populations requiring two-point sampling by examining risk factors associated with AUC discrepancies between one- and two-point sampling during follow-up therapeutic drug monitoring (TDM). Method: This multicenter retrospective observational study included adult patients who received vancomycin from September 2020 to December 2023 and underwent two-point sampling at both initial and follow-up TDM. AUC was estimated using the Practical Antimicrobial TDM (PAT) version 4.0, and creatinine clearance (CLcr) was calculated using the Cockcroft-Gault equation. One- and two-point follow-up AUCs were compared using previously entered two-point concentrations from initial TDM. Patients were divided into a discrepancy group (AUC difference ≥10 %) and a non-discrepancy group. Risk factors were identified by univariate and multivariate analysis. Results: AUC values from one- and two-point sampling in 256 cases were highly correlated (r<sup>2</sup> = 0.965, p < 0.001). Seventeen cases (6.6 %) showed discrepancies ≥10 %. Multivariate analysis identified BMI ≥25 kg/m<sup>2</sup> (OR = 6.946, p = 0.001), CLcr <50 mL/min (OR = 5.863, p = 0.002), and ΔCLcr ≥10 mL/min (OR = 4.444, p = 0.012) as significant risk factors. Conclusion: Although one- and two-point AUCs showed strong correlation, discrepancies ≥10 % were more likely in patients with elevated BMI or impaired/unstable renal function. This suggests that two-point sampling may be essential for these patients to ensure accurate dosing of vancomycin during follow-up TDM.

  • Efficacy and Safety of Isavuconazole for Invasive Fungal Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    Kawasaki A, Shintani R, Takao R, Nakazawa Y, Mihara T, Ikegami S, Shimada S, Matsumoto Y, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K

    Medical mycology 63 ( 10 )  2025.09

    Joint Work,  ISSN  1369-3786

    　View Summary

    Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.

    Yoshikawa M, Nishimura T, Misawa K, Shimamura R, Suzuki K, Kashimura S, Igarashi Y, Enoki Y, Taguchi K, Hasegawa N, Namkoong H, Matsumoto K

    Microbiology spectrum 13 ( 11 ) e0201225 - 15 2025.09

    Joint Work

    　View Summary

    The global incidence and prevalence of pulmonary disease caused by the Mycobacterium avium complex (MAC), mainly comprising M. avium and Mycobacterium intracellulare, is increasing. However, treating MAC pulmonary disease is challenging in cases of clarithromycin (CLR)-resistant MAC or where the patients experience adverse effects or drug interactions with the few available antibiotics. Therefore, developing novel and highly effective antibiotics against MAC is crucial. Although the efficacy of dual β-lactams against Mycobacterium abscessus has been receiving attention, the efficacy of dual β-lactams against MAC remains unclear. Here, we used MAC type strains and clinical isolates to determine whether dual β-lactams were effective against MAC and which combinations synergistically inhibited bacterial growth using a broth microdilution checkerboard assay with 6 oral and 22 intravenous antibiotics. The combination effect and antibacterial activity differed between M. avium and M. intracellulare. Five combinations of oral β-lactams and 78 combinations of intravenous β-lactams showed a synergistic effect against the M. avium type strain. Among the M. avium clinical isolates, faropenem combined with cefuroxime showed the highest synergistic effect, and amoxicillin combined with tebipenem showed the lowest minimum inhibitory concentration. There was no significant difference in the combination effects between the CLR-susceptible and CLR-resistant M. avium clinical isolates in these pairs. In conclusion, regardless of CLR susceptibility, the oral β-lactam combinations were effective against M. avium. Thus, when treating MAC pulmonary disease, it is crucial to determine whether M. avium or M. intracellulare is the cause. IMPORTANCE Mycobacterium avium complex causes chronic respiratory infections, but treatment is often limited by drug resistance, intolerance, or interactions. As new therapeutic strategies are urgently needed, we focused on β-lactam antibiotics, which are widely used and well tolerated. Although dual β-lactams are effective against Mycobacterium abscessus, their utility against Mycobacterium avium complex has remained largely unexplored. Our in vitro study revealed that several β-lactam combinations are effective against Mycobacterium avium, regardless of drug resistance, indicating potential for clinical use. In contrast, Mycobacterium intracellulare showed lower susceptibility to β-lactams. Given this difference in drug susceptibility, we emphasize the clinical need to distinguish Mycobacterium avium and Mycobacterium intracellulare to optimize treatment of Mycobacterium avium complex pulmonary disease.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • COVID-19抗ウイルス薬の薬物間相互作用

    松元 一明

    内科総合誌Medical Practice ((株)文光堂)  42 ( 12 ) 1875 - 1879 2025.12

    ISSN  0910-1551

  • 抗菌薬治療におけるPK/PD理論の応用と実践

    松元 一明

    医療関連感染 (東京医療保健大学大学院)  18 ( 1 ) 1 - 8 2025.12

    ISSN  2187-9028

  • 抗菌薬の持続投与を再考する

    松元 一明

    J-IDEO ((株)中外医学社)  9 ( 4 ) 516 - 524 2025.07

    ISSN  2432-7077

  • 感染制御に現場から一言　抗菌薬適正使用における薬剤師の役割

    松元 一明

    感染と消毒 (サラヤ(株))  32 ( 1 ) 52 - 55 2025.05

    ISSN  1346-2326

    　View Summary

    抗菌薬適正使用における薬剤師の役割は,益々重要になってきている.また,その役割は働いている施設により異なる.感染症診断の支援から携わる場合,抗菌薬選択または投与量設計から関わる場合もある.いずれにせよ科学的根拠に基づいて実施すべきである.本項では抗菌薬選択,投与量設計としてPK/PD,TDMの考え方について述べる.(著者抄録)

  • 抗微生物薬適正使用支援プログラム実践のためのガイダンス　2024年度改訂版

    川口 辰哉, 賀来 満夫, 青木 洋介, 小阪 直史, 関 雅文, 田邊 嘉也, 藤田 直久, 前田 真之, 村木 優一, 森田 邦彦, 柳原 克紀, 山田 武宏, 吉田 耕一郎, 二木 芳人, 菅野 みゆき, 菅原 えりさ, 清祐 麻紀子, 高橋 俊司, 山本 剛, 松元 一明, 池田 賢二, 篠原 孝幸, 山岸 由佳, 公益社団法人日本化学療法学会, 一般社団法人日本感染症学会・一般社団法人日本環境感染学会・一般社団法人日本臨床微生物学会・公益社団法人日本薬学会・一般社団法人日本医療薬学会・一般社団法人日本TDM学会・一般社団法人日本医真菌学会8学会合同抗微生物薬適正使用推進検討委員会

    感染症学雑誌 ((一社)日本感染症学会)  99 ( 2 ) 95 - 156 2025.03

    ISSN  0387-5911

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • ポサコナゾールの血清タンパク質への結合特性の解析.

    岡本侑子、田口和明、五十嵐裕貴、榎木裕紀、松元一明.

    [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

    2025.11
    , 

    Poster presentation

  • CREによる肺炎マウスモデルを用いたNAC/CFPM併用療法時の目標T>MICi値.

    水上雄貴、岡本侑子、五十嵐裕貴、榎木裕紀、田口和明、池上眞太郎、鈴木健太、高橋実秀、松元一明.

    [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

    2025.11
    , 

    Oral presentation (general)

  • バンコマイシンの2回目TDMにおける2点採血の必要性.

    鈴木絢子、藤原久登、山口史博、吉田博昭、田中宏明、八木祐助、浜田幸宏、石郷友之、藤居賢、南雲史雄、佐村優、千葉博暁、海老原文哉、丸山拓実、詫間章俊、小松敏彰、冨澤淳、西圭史、五十嵐裕貴、榎木裕紀、松元一明.

    [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

    2025.11
    , 

    Oral presentation (general)

  • 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない.

    石郷友之、鈴木絢子、藤居賢、伊部裕太、福土将秀、吉田博昭、田中宏明、海老原文哉、丸山拓実、八木祐助、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、五十嵐裕貴、榎木裕紀、浜田幸宏、西圭史、松元一明.

    [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

    2025.11
    , 

    Oral presentation (general)

  • シンポジウム3：薬剤師と真菌感染症「抗真菌薬の適正使用のためのガイドラインの潮流」

    松元一明.

    [Domestic presentation]  第69回日本医真菌学会総会・学術集会 (高知県) , 

    2025.10
    , 

    Symposium, workshop panel (nominated)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

    2024.04
    -
    2028.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発

    2023.08
    -
    2024.03

    国立研究開発法人日本医療研究開発機構（AMED）, 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

  • ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究

    2022.04
    -
    2025.03

    国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

  • マウス肺感染モデルを用いたOP0595の臨床有効性予測

    2022.01
    -
    2024.03

    Meiji Seikaファルマ株式会社, Commissioned ｒesearch, Principal investigator

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

    2021.09
    -
    2023.08

    大日本住友製薬株式会社, Commissioned ｒesearch, Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied： 特願2020-144044  2020.08 

    Patent, Joint

Page Top ▲

Awards 【 Display / hide 】

  • 第35回日本医療薬学会年会優秀演題賞

    石郷友之、鈴木絢子、藤居賢、伊部裕太、福土将秀、吉田博昭、田中宏明、海老原文哉、丸山拓実、八木祐助、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、五十嵐裕貴、榎木裕紀、浜田幸宏、西圭史、松元一明, 2025.11, 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

  • 第17回日本化学療法学会東日本支部 支部奨励賞（基礎）

    鈴木健太、島村莉奈、吉川万衣子、宇山杏奈、林侑孝、五十嵐裕貴、榎木裕紀、西村知泰、松元一明, 2025.09, Hollow Fiber Infection Modelを用いた肺MAC症に対する標準治療の有効性評価

  • 第8回フレッシャーズ・カンファランス優秀演題発表賞

    島村莉奈, 西村知泰, 吉川万衣子, 三澤可奈, 矢野大和, 榎木裕紀, 五十嵐裕貴, 長谷川直樹, 南宮湖, 松元一明, 2025.06, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態の変化

  • 日本薬学会第145年会 学生優秀発表賞受賞（口頭発表）

    三原貴之、松本ゆうり、坪内愛佑、池上眞太郎、高橋実秀、中林花音、西本直人、水上雄貴、村石琢真、榎木裕紀、田口和明、松元一明, 2025.04, 肺炎球菌感染症に対する13価、23価肺炎球菌ワクチンの併用と23価肺炎球菌ワクチン単剤接種の有効性および安全性比較：システマティックレビュー＆メタ解析

  • 日本薬学会第145年会 学生優秀発表賞受賞（口頭発表）

    杉本唯衣, 佐々木崚介, 富永真由, 平井柳佳, 三原貴之, 榎木裕紀, 田口和明, 松元一明, 2025.04, 腸球菌による感染性心内膜炎に対するβラクタム系薬2剤併用とβラクタム系薬/アミノグリコシド系薬併用の有効性及び安全性比較：システマティックレビュー, メタ解析

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2025

  • SEMINAR (PHARMACODYNAMICS)

    2025

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2025

  • RESEARCH FOR BACHELOR'S THESIS 1

    2025

  • PROJECT FOR MULTIDISCIPLINARY AND INTERDISCIPLINARY KNOWLEDGE (SUSTAINABLE ENVIRONMENT)

    2025

display all >>

Page Top ▲
 

Social Activities 【 Display / hide 】

Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本医真菌学会, 

    2019.02
    -
    Present

  • 日本DDS学会, 

    2018.05
    -
    Present

  • 日本臨床微生物学会, 

    2018.03
    -
    Present

  • 日本老年薬学会　理事・評議員, 

    2016.04
    -
    Present

  • 日本薬剤学会　代議員, 

    2015.12
    -
    Present

display all >>

Page Top ▲